CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
- Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making
- Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.